ELSEVIER

Atherosclerosis 127 (1996) 291–293

ATHEROSCLEROSIS

# Author index

## Volume 127 (1996)

A. Ades, P., see Fonong, T. **127**, 177
Abbot, S.E., see Thorne, S.A. **127**, 167
Ahmadi, R., see Maca, T. **127**, 27
Alain Simon, see Linhart, A. **127**, 103
Aro, A., see Öhrvall, M. **127**, 65
Aston, C.E., see Kamboh, M.I. **127**, 255
Auerbach, B.J., see Krause, B.R. **127**, 91

Balagtas, C.C., see Schaefer, E.J. **127**, 113
Barnett, B.C., see Krause, B.R. **127**, 91
Berenson, G.S., see Srinivasan, S.R. **127**, 73
Berglund, L., see Öhrvall, M. **127**, 65
Bisgaier, C.L., see Krause, B.R. **127**, 91
Black, D.M., see Schaefer, E.J. **127**, 113
Blake, D.R., see Thorne, S.A. **127**, 167
Bobryshev, Y.V., J.A. Crozier, R.S.A. Lord, D. Tran, O.S. Jamal, H.N. Pärsson, K.F. Scott, Expression of secretory group II phospholipase A2 by CD1a positive cells in human atherosclerotic plaques **127**, 283
Bode-Böger, S.M., see Böger, R.H. **127**, 1
Böger, R.H., S.M. Bode-Böger, J.C. Frölich, The L-arginine–nitric oxide pathway: role in atherosclerosis and therapeutic implications **127**, 1
Bousley, R., see Krause, B.R. **127**, 91
Brüel, A., H. Oxlund, Changes in biomechanical properties, composition of collagen and elastin, and advanced glycation endproducts of the rat aorta in relation to age **127**, 155
Byrne, C.D., N.J. Wareham, P.K. Mistry, D.I.W. Phillips, N.D. Martensz, D. Halsall, P.J. Talmud, S.E. Humphries, C.N. Hales, The association between free fatty acid concentrations and triglyceride-rich lipoproteins in the post-prandial state is altered by a common deletion polymorphism of the apo B signal peptide **127**, 35

Calles-Escandon, J., see Fonong, T. **127**, 177
Casao, E., see Civeira, F. **127**, 273
Castro, G., see Syvänne, M. **127**, 245
Catapano, A.L., see Lambert, D.A. **127**, 205
Catapano, A.L., see Roma, P. **127**, 147
Cenarro, A., see Civeira, F. **127**, 273
Chen, W.-J., S.-Y. Lin-Shiau, H.-C. Huang, Y.-T. Lee, Ischemia-induced alteration of myocardial $Na^+$-$K^+$-ATPase activity and ouabain binding sites in hypercholesterolemic rabbits **127**, 59
Chen, Y.-L., see Liu, M.W. **127**, 221
Cilla Jr, D.D., see Schaefer, E.J. **127**, 113
Civeira, F., M. Pocoví, A. Cenarro, E. Casao, E. Vilella, J. Joven, J. González, A.L. Garcia-Otín, J.M. Ordovás, Apo E variants in patients with type III hyperlipoproteinemia **127**, 273
Cole, T., see Schaefer, E.J. **127**, 113
Crozier, J.A., see Bobryshev, Y.V. **127**, 283

De Geitere, C., see Syvänne, M. **127**, 245
Dengremont, C., see Syvänne, M. **127**, 245
Derfler, K., see Maca, T. **127**, 27
Du, R.Y., see He, Y. **127**, 229

Ehnholm, C., see Srinivasan, S.R. **127**, 73
Ehnholm, C., see Syvänne, M. **127**, 245
Ehringer, H., see Maca, T. **127**, 27
Elkhalil, L., see Luc, G. **127**, 131
Essenburg, A.D., see Krause, B.R. **127**, 91

Figueroa, J.E., see Vijayagopal, P. **127**, 195
Fonong, T., M.J. Toth, P. A. Ades, L.I. Katzel, J. Calles-Escandon, E.T. Poehlman, Relationship between physical activity and HDL-cholesterol in healthy older men and women: a cross-sectional and exercise intervention study **127**, 177
Fontenot, J.D., see Vijayagopal, P. **127**, 195
Franceschini, G., see Syvänne, M. **127**, 245
Frölich, J.C., see Böger, R.H. **127**, 1
Fujiwara, R., T. Nakai, Effects of glucose, insulin, and insulin-like growth factor-I on glucose transport activity in cultured rat vascular smooth muscle cells **127**, 49

Ganotakis, E.S., see Mikhailidis, D.P. **127**, 287
Garcia-Otín, A.L., see Civeira, F. **127**, 273
Gariepy, J., see Linhart, A. **127**, 103
Giral, P., see Linhart, A. **127**, 103
Glancy, D.L., see Vijayagopal, P. **127**, 195
González, J., see Civeira, F. **127**, 273
Gotto Jr., A.M., see Lambert, D.A. **127**, 205
Groszek, L., see Lin, J.H.-C. **127**, 185
Gylling, H., H. Relas, H.E. Miettinen, R. Radhakrishnan, T.A. Miettinen, Delayed postprandial retinyl palmitate and squalene removal in a patient heterozygous for apolipoprotein A-$I_{FIN}$ mutation (Leu 159→Arg) and low HDL cholesterol level without coronary artery disease **127**, 239

Hales, C.N., see Byrne, C.D. **127**, 35
Halsall, D., see Byrne, C.D. **127**, 35
Hamman, R.F., see Kamboh, M.I. **127**, 255
He, Y., T.H. Lam, L.S. Li, L.S. Li, R.Y. Du, G.L. Jia, J.Y. Huang, J.S. Zheng, The number of stenotic coronary arteries and passive smoking exposure from husband in lifelong non-smoking women in Xi'an, China **127**, 229
Hörl, W.-H., see Maca, T. **127**, 27
Huang, H.-C., see Chen, W.-J. **127**, 59
Huang, J.Y., see He, Y. **127**, 229
Humphries, S.E., see Byrne, C.D. **127**, 35

Ikäheimo, M., see Korhonen, T. **127**, 213

Jamal, O.S., see Bobryshev, Y.V. **127**, 283
Jauhiainen, M., see Syvänne, M. **127**, 245
Jean-Charles Fruchart, see Luc, G. **127**, 131
Jia, G.L., see He, Y. **127**, 229
Joven, J., see Civeira, F. **127**, 273

Kahri, J., see Syvänne, M. **127**, 245
Kamboh, M.I., C.E. Aston, C.M. Nestlerode, A.E. McAllister, R.F. Hamman, Haplotype analysis of two APOA1/*MspI* polymorphisms in relation to plasma levels of Apo A-I and HDL-cholesterol **127**, 255
Katzel, L.I., see Fonong, T. **127**, 177
Kervinen, K., see Korhonen, T. **127**, 213
Kesäniemi, Y.A., see Korhonen, T. **127**, 213
Khachadurian, A.K., see Rifici, V.A. **127**, 19
Kieft, K.A., see Krause, B.R. **127**, 91
Kobari, Y., see Lin, J.H.-C. **127**, 185
Koistinen, M.J., see Korhonen, T. **127**, 213
Koppensteiner, R., see Maca, T. **127**, 27
Korhonen, T., M.J. Savolainen, M.J. Koistinen, M. Ikäheimo, M.K. Linnaluoto, K. Kervinen, Y.A. Kesäniemi, Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women **127**, 213
Krause, B.R., B.C. Barnett, A.D. Essenburg, K.A. Kieft, B.J. Auerbach, R. Bousley, R. Stanfield, R.S. Newton, C.L. Bisgaier, Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats **127**, 91
Kuroiwa, A., see Nakashima, Y. **127**, 43

Lambert, D.A., A.L. Catapano, L.C. Smith, J.T. Sparrow, A.M. Gotto Jr., Effect of the apolipoprotein C-II/C-$III_1$ ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles **127**, 205
Lamon-Fava, S., see Schaefer, E.J. **127**, 113
Lam, T.H., see He, Y. **127**, 229
Lee, Y.-T., see Chen, W.-J. **127**, 59
Lehmann, E.D., Functional abnormalities of the aorta **127**, 139
Levenson, J., see Linhart, A. **127**, 103
Liao, H.L., see Lin, J.H.-C. **127**, 185
Li, L.S., see He, Y. **127**, 229
Li, L.S., see He, Y. **127**, 229
Linhart, A., J. Gariepy, P. Giral, J. Levenson, Alain Simon, Carotid artery and left ventricular structural relationship in asymptomatic men at risk for cardiovascular disease **127**, 103
Lin, J.H.-C., Y. Zhu, H.L. Liao, Y. Kobari, L. Groszek, M.B. Stemerman, Induction of vascular cell adhesion molecule-1 by low-density lipoprotein **127**, 185
Linnaluoto, M.K., see Korhonen, T. **127**, 213
Lin-Shiau, S.-Y., see Chen, W.-J. **127**, 59
Lin, S.-J., see Liu, M.W. **127**, 221
Lithell, H., see Öhrvall, M. **127**, 65
Liu, M.W., S.-J. Lin, Y.-L. Chen, Local alcohol delivery may reduce phenotype conversion of smooth muscle cells and neointimal formation in rabbit iliac arteries after balloon injury **127**, 221
Lord, R.S.A., see Bobryshev, Y.V. **127**, 283
Lottenberg, A.M.P., see Lottenberg, S.A. **127**, 81
Lottenberg, S.A., A.M.P. Lottenberg, V.S. Nunes, R. McPherson, E.C.R. Quintão, Plasma cholesteryl ester transfer protein concentration, high-density lipoprotein cholesterol esterification and transfer rates to lighter density lipoproteins in the fasting state and after a test meal are similar in Type II diabetics and normal controls **127**, 81
Luc, G., Z. Majd, P. Poulain, L. Elkhalil, Jean-Charles Fruchart, Interstitial fluid apolipoprotein A-II: an association with the occurrence of myocardial infarction **127**, 131

Maca, T., R. Ahmadi, K. Derfler, W.-H. Hörl, R. Koppensteiner, E. Minar, B. Schneider, A. Stümpflen, H. Ehringer, Elevated Lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? **127**, 27
Majd, Z., see Luc, G. **127**, 131
Makino, N., see Sugano, M. **127**, 123
Martensz, N.D., see Byrne, C.D. **127**, 35
McAllister, A.E., see Kamboh, M.I. **127**, 255
McPherson, R., see Lottenberg, S.A. **127**, 81
Michelagnoli, S., see Syvänne, M. **127**, 245
Miettinen, H.E., see Gylling, H. **127**, 239
Miettinen, T.A., see Gylling, H. **127**, 239
Mikhailidis, D.P., E.S. Ganotakis, A.F. Winder, Comment on: Effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia **127**, 287

Mills, P.G., see Thorne, S.A. **127**, 167
Minar, E., see Maca, T. **127**, 27
Mistry, P.K., see Byrne, C.D. **127**, 35

Nakai, T., see Fujiwara, R. **127**, 49
Nakashima, Y., T. Toyokawa, S. Tanaka, K. Yamashita, A. Yashiro, H. Tasaki, A. Kuroiwa, Simvastatin increases plasma $NO_2^-$ and $NO_3^-$ levels in patients with hypercholesterolemia **127**, 43
Nestlerode, C.M., see Kamboh, M.I. **127**, 255
Newton, R.S., see Krause, B.R. **127**, 91
Niculescu, F., see Rus, H.G. **127**, 263
Nunes, V.S., see Lottenberg, S.A. **127**, 81

Öhrvall, M., L. Berglund, I. Salminen, H. Lithell, A. Aro, B. Vessby, The serum cholesterol ester fatty acid composition but not the serum concentration of alpha tocopherol predicts the development of myocardial infarction in 50-year-old men: 19 years follow-up **127**, 65
Ordovás, J.M., see Civeira, F. **127**, 273
Oxlund, H., see Brüel, A. **127**, 155

Pärsson, H.N., see Bobryshev, Y.V. **127**, 283
Phillips, D.I.W., see Byrne, C.D. **127**, 35
Pocoví, M., see Civeira, F. **127**, 273
Poehlman, E.T., see Fonong, T. **127**, 177
Poulain, P., see Luc, G. **127**, 131

Quintão, E.C.R., see Lottenberg, S.A. **127**, 81

Radhakrishnan, R., see Gylling, H. **127**, 239
Rainwater, D.L., Lp(a) concentrations are related to plasma lipid concentrations **127**, 13
Relas, H., see Gylling, H. **127**, 239
Rifici, V.A., A.K. Khachadurian, Effects of dietary vitamin C and E supplementation on the copper mediated oxidation of HDL and on HDL mediated cholesterol efflux **127**, 19
Roma, P., A.L. Catapano, Stress proteins and atherosclerosis **127**, 147
Rowan, J.P., see Schaefer, E.J. **127**, 113
Rus, H.G., R. Vlaicu, F. Niculescu, Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall **127**, 263

Salminen, I., see Öhrvall, M. **127**, 65
Savolainen, M.J., see Korhonen, T. **127**, 213
Schaefer, E.J., S. Lamon-Fava, T. Cole, D.L. Sprecher, D.D. Cilla Jr, C.C. Balagtas, J.P. Rowan, D.M. Black, Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels **127**, 113
Schneider, B., see Maca, T. **127**, 27
Scott, K.F., see Bobryshev, Y.V. **127**, 283
Smith, L.C., see Lambert, D.A. **127**, 205
Sparrow, J.T., see Lambert, D.A. **127**, 205
Sprecher, D.L., see Schaefer, E.J. **127**, 113
Srinivasan, S.R., C. Ehnholm, W.A. Wattigney, G.S. Berenson, Influence of apolipoprotein E polymorphism on the tracking of childhood levels of serum lipids and apolipoproteins over a 6-year period. The Bogalusa Heart Study **127**, 73
Stanfield, R., see Krause, B.R. **127**, 91
Stemerman, M.B., see Lin, J.H.-C. **127**, 185
Stevens, C.R., see Thorne, S.A. **127**, 167
Stümpflen, A., see Maca, T. **127**, 27
Sugano, M., N. Makino, T. Yanaga, The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits **127**, 123
Syvänne, M., G. Castro, C. Dengremont, C. De Geitere, M. Jauhiainen, C. Ehnholm, S. Michelagnoli, G. Franceschini, J. Kahri, M.-R. Taskinen, Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein **127**, 245

Talmud, P.J., see Byrne, C.D. **127**, 35
Tanaka, S., see Nakashima, Y. **127**, 43
Tasaki, H., see Nakashima, Y. **127**, 43
Taskinen, M.-R., see Syvänne, M. **127**, 245
Thorne, S.A., S.E. Abbot, C.R. Stevens, P.G. Winyard, P.G. Mills, D.R. Blake, Modified low density lipoprotein and cytokines mediate monocyte adhesion to smooth muscle cells **127**, 167
Toth, M.J., see Fonong, T. **127**, 177
Toyokawa, T., see Nakashima, Y. **127**, 43
Tran, D., see Bobryshev, Y.V. **127**, 283
Tsuda, Y., Response to Mikhailidis et al. **127**, 289

Vessby, B., see Öhrvall, M. **127**, 65
Vijayagopal, P., J.E. Figueroa, J.D. Fontenot, D.L. Glancy, Isolation and characterization of a proteoglycan variant from human aorta exhibiting a marked affinity for low density lipoprotein and demonstration of its enhanced expression in atherosclerotic plaques **127**, 195
Vilella, E., see Civeira, F. **127**, 273
Vlaicu, R., see Rus, H.G. **127**, 263

Wareham, N.J., see Byrne, C.D. **127**, 35
Wattigney, W.A., see Srinivasan, S.R. **127**, 73
Winder, A.F., see Mikhailidis, D.P. **127**, 287
Winyard, P.G., see Thorne, S.A. **127**, 167

Yamashita, K., see Nakashima, Y. **127**, 43
Yanaga, T., see Sugano, M. **127**, 123
Yashiro, A., see Nakashima, Y. **127**, 43

Zheng, J.S., see He, Y. **127**, 229
Zhu, Y., see Lin, J.H.-C. **127**, 185

ELSEVIER

Atherosclerosis 127 (1996) 295–296

ATHEROSCLEROSIS

# Subject index

## Volume 127 (1996)

Adiposity **127**, 177
Ageing **127**, 155
Alcohol **127**, 221
Angiography **127**, 229
Angiotensin-converting enzyme inhibitor **127**, 123
Angiotensin II receptor antagonist **127**, 123
Antioxidant vitamins **127**, 19
Aorta **127**, 139, 155
AP-1 **127**, 185
Apo B lipoproteins **127**, 81
Apo $E_{Christchurch}$ **127**, 273
Apo E genotyping **127**, 273
Apo E polymorphism **127**, 73
Apo E polymorphisms **127**, 273
Apolipoprotein(a) **127**, 13
Apolipoprotein(a) genotypes **127**, 13
Apolipoprotein A-I **127**, 255
Apolipoprotein A-I mutation **127**, 239
Apolipoprotein B **127**, 35
Apolipoprotein B-48 **127**, 239
Apolipoprotein E **127**, 213, 273
Apolipoproteins **127**, 91, 131, 205
Apolipoprotein-specific particles **127**, 245
Arteriosclerosis **127**, 229
Atherogenesis **127**, 195, 263
Atherosclerosis **127**, 1, 123, 147, 283

Balloon injury **127**, 221
Biomechanics **127**, 155
−75 bp **127**, 255
+83 bp **127**, 255

Calcification **127**, 283
Cardiovascular risk factors **127**, 103
Carotid artery **127**, 103
C5b-9 **127**, 263
CD1a **127**, 283
Childhood risk factors **127**, 73
Cholesterol **127**, 13, 91, 113
Cholesterol efflux **127**, 19
Cholesterol-lowering agent **127**, 43
Cholesteryl ester transfer protein **127**, 81
Collagen **127**, 155
Complement activation **127**, 263
Compliance **127**, 139
Coronary **127**, 229
Coronary artery disease **127**, 239
Coronary smooth muscle cells **127**, 167
Coronary stenosis **127**, 213
Cytotoxic stimuli **127**, 147

Distensibility **127**, 139
Dysbetalipoproteinemia **127**, 273

E-4177 **127**, 123
Echocardiography **127**, 103
Elastin **127**, 155
Elderly **127**, 177
Enalapril **127**, 123
Endothelial cells **127**, 185
Environmental tobacco smoke **127**, 229
Epidemiologic methods **127**, 229
Extent of coronary disease **127**, 229

Fatty acid composition **127**, 65
Female **127**, 213
Fibrates **127**, 91
Foam cell formation **127**, 195
Free fatty acid **127**, 35

GATA **127**, 185
Gemfibrozil **127**, 113
Genotype **127**, 35
Glucose transport activity **127**, 49
Glycation **127**, 155

Haplotypes **127**, 255
HDL-C **127**, 177
HDL cholesterol **127**, 239
High density lipoprotein **127**, 113

High-density lipoprotein **127**, 81
High density lipoprotein **127**, 19
High density lipoproteins **127**, 245
Human **127**, 13
Hypercholesterolemia **127**, 43, 59, 185
hypercholestrolemic **127**, 289

IL-8 **127**, 263
IL-6 **127**, 263
Inflammation **127**, 283
Insulin **127**, 49
Insulin-like growth factor-I **127**, 49
Insulin resistance **127**, 49
Interstitial fluid **127**, 131
Intimal hyperplasia **127**, 221
Intima–media thickness **127**, 103
In vitro cholesterol efflux **127**, 245
Ischemia **127**, 59

L-Arginine **127**, 1
LDL-binding **127**, 195
LDL/HDL ratio **127**, 65
Lecithin cholesterol acyltransferase **127**, 81
Lecithin:cholesteryl acyltransferase **127**, 245
Left ventricular mass **127**, 103
Linkage disequilibrium **127**, 255
Lipid transfer proteins **127**, 245
Lipoprotein(a) **127**, 13, 27
Lipoprotein lipase **127**, 205
Lipoproteins **127**, 73, 91, 131
Low density lipoprotein **127**, 113, 167

Male **127**, 213
Monocyte adhesion **127**, 167
Myocardial infarction **127**, 65, 131

$Na^+$-$K^+$-ATPase **127**, 59
Nitric oxide **127**, 1
Non-insulin dependent diabetes mellitus **127**, 81
Non-smokers **127**, 255

Ouabain receptor **127**, 59
Oxidation **127**, 19

Percutaneous transluminal angioplasty **127**, 27
Peripheral arterial occlusive disease **127**, 27
Phosphatidylinositol 3-kinase **127**, 49
Phospholipase A2 **127**, 283
Physical activity **127**, 177
Plasma fibrinogen **127**, 287, 289
Plasma lipids **127**, 213
Plasma nitrite and nitrate **127**, 43
Postprandial lipoproteins **127**, 239
Pravastatin **127**, 287
Pravastatin sodium **127**, 289
Promoter activation **127**, 185
Protein cofactors **127**, 205
Proteoglycans **127**, 195
Pulse wave velocity **127**, 139

Restenosis **127**, 27
Retinyl palmitate **127**, 239
Reverse cholesterol transport **127**, 245

Simvastatin **127**, 287, 289
Smooth muscle cells **127**, 221
Squalene **127**, 239
Stiffness **127**, 139
Stress proteins **127**, 147
Systolic blood pressure **127**, 65

Therapeutic implications **127**, 1
Tocopherol **127**, 65
Tracking **127**, 73
Triacylglycerides **127**, 13
Triglyceride **127**, 35, 91
Triglyceride-rich lipoprotein **127**, 35
Triglycerides **127**, 113
Type II hyperlipoproteinemia **127**, 287
Type III hyperlipoproteinemia **127**, 273

US Whites **127**, 255

Vascular adhesion molecule **127**, 185
Vascular dendritic cells **127**, 283
Vascular smooth muscle cells **127**, 49